Parnell Pharmaceuticals Holdings Ltd (PARNF) Research

Parnell Pharmaceuticals Holdings Ltd is a well-established biopharmaceutical company that focuses on the entire lifecycle of animal health solutions, from development and manufacturing to global distribution. The company organizes its operations into four distinct business units: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. Its diverse product portfolio includes key offerings like estroPLAN and GONAbreed, which are hormone-based treatments designed to enhance reproductive performance in cattle. For addressing osteoarthritis, Parnell provides Zydax, a therapeutic injection for dogs and horses, as well as Glyde, a nutraceutical supplement. The company further offers Parnell PROcept, a protocol that incorporates an additional estroPLAN injection. Beyond pharmaceutical products, Parnell also developed mySYNCH, a digital platform crafted to assist veterinarians and livestock producers in streamlining reproduction management and improving economic yields. Parnell Pharmaceuticals Holdings Ltd was founded in 2009 and maintains its corporate headquarters in Alexandria, Australia.

Open Parnell Pharmaceuticals Holdings Ltd (PARNF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.